What Is Tesamorelin?
Tesamorelin is a synthetic analogue of endogenous growth hormone-releasing hormone (GHRH), also known as growth hormone-releasing factor (GRF). The compound consists of the full 44 amino acid sequence of human GHRH with the addition of a trans-3-hexenoic acid group at the N-terminus. This modification confers stability against dipeptidyl peptidase IV (DPP-IV) cleavage, which rapidly degrades unmodified GHRH in vivo, extending the compound's biological half-life and making it more practical for experimental study.
Tesamorelin is notable among research peptides for having undergone the most extensive human clinical trial program of any compound in its class. It received FDA approval in 2010 under the trade name Egrifta for the treatment of HIV-associated lipodystrophy, a metabolic condition characterized by excess visceral adipose tissue accumulation in patients on antiretroviral therapy.
Mechanism of Action
Tesamorelin acts on pituitary somatotroph cells by binding to GHRH receptors (GHRHR), stimulating the pulsatile release of endogenous growth hormone (GH). Unlike exogenous GH administration, tesamorelin preserves the physiological pulsatility of GH secretion and maintains feedback regulation through somatostatin, properties that distinguish its pharmacological profile from direct GH administration.
The increase in GH secretion drives downstream elevation of IGF-1 (insulin-like growth factor 1), which is largely responsible for the anabolic and lipolytic effects observed in clinical studies. Because tesamorelin stimulates rather than replaces endogenous GH, the hypothalamic-pituitary axis regulatory mechanisms remain intact.
Phase III Clinical Trial Data
The pivotal clinical program for tesamorelin comprised two randomized, double-blind, placebo-controlled Phase III trials published by Falutz et al. in the New England Journal of Medicine (2007) and the Journal of Clinical Endocrinology & Metabolism (2010). In the primary efficacy study, 412 HIV-positive patients with abdominal lipodystrophy were randomized to receive tesamorelin or placebo for 26 weeks. The tesamorelin group demonstrated statistically significant reductions in visceral adipose tissue (VAT) as measured by CT scan, with a mean reduction of approximately 15–18% compared to minimal change in the placebo group.
Secondary endpoints showed significant increases in IGF-1 levels and improvements in lipid profiles (triglycerides, HDL cholesterol) in the treatment group. The extension phase of the study confirmed that continued tesamorelin administration maintained VAT reductions, while discontinuation led to reaccumulation, consistent with the compound's mechanism of sustaining GH axis activity rather than permanent metabolic reprogramming.
GH/IGF-1 Axis Research
Researchers have used tesamorelin as a tool compound to study the GH/IGF-1 axis in contexts beyond HIV lipodystrophy. Studies have examined its effects on body composition in GH-deficient adults, cognitive function in older adults with mild cognitive impairment, and metabolic parameters in subjects with abdominal obesity. A notable study by Friedman et al. (2018) in JAMA Neurology examined tesamorelin's effects on cognition and brain amyloid in older adults at risk for Alzheimer's disease, finding improvements in executive function and verbal memory in the treatment group.
Safety Profile from Clinical Data
The clinical trial data for tesamorelin provide a more complete safety characterization than is available for most research peptides. Observed adverse effects in studies included edema, arthralgia, and myalgia, consistent with GH axis activation, as well as glucose metabolism effects requiring monitoring in subjects with impaired glucose tolerance. The FDA-approved prescribing information for Egrifta provides the most authoritative safety summary for this compound.
Why Tesamorelin Matters to Peptide Researchers
Tesamorelin occupies a unique position in the peptide research landscape: it is one of the few compounds in this class with robust human clinical trial data spanning multiple therapeutic areas. This body of evidence provides a reference point for understanding the pharmacological effects of GHRH receptor stimulation in human subjects, data directly relevant to researchers studying GH axis biology, body composition regulation, and the metabolic consequences of GH deficiency or excess.
Selected References
- Falutz J, et al. (2007). Metabolic Effects of a Growth Hormone–Releasing Factor in Patients with HIV. New England Journal of Medicine, 357(23):2359–2370.
- Falutz J, et al. (2010). Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension. Journal of Acquired Immune Deficiency Syndromes, 53(3):311–22.
- Stanley TL, et al. (2012). Reduction in visceral adiposity is associated with an improved metabolic profile in HIV-infected patients receiving tesamorelin. Clinical Infectious Diseases, 54(11):1642–51.
- Friedman SD, et al. (2013). Growth Hormone-Releasing Hormone Effects on Brain γ-Aminobutyric Acid Levels in Mild Cognitive Impairment and Healthy Aging. JAMA Neurology, 70(7):883–90.
- Falutz J. (2011). Tesamorelin: a novel therapeutic option for HIV/HAART-associated increased visceral adipose tissue. Drugs Today (Barc), 47(6):419–30.